Browsing Tag
AstraZeneca
154 posts
Avacta (AIM: AVCT) just paid down £3.67m of bond debt in cash. The real question is what AVA6103 does next.
Avacta cleared bond debt in cash and reaches its AVA6103 readout on funded runway. The next six months decide whether pre|CISION reads as one drug or a platform.
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
Racura Oncology (ASX:RAC): Will HARNESS-1 reset its valuation?
Racura Oncology has funded three cancer trials, but RAC shares remain far below their high. HARNESS-1 must now turn clinical progress into evidence.
AstraZeneca Pharma India exits factory licence as #ASTRAZEN investors assess asset-light model
AstraZeneca Pharma India surrendered its factory licence as #ASTRAZEN exits manufacturing. Find out what the shift means for investors.
Why clinicians and regulators are closely watching AstraZeneca’s rare disease and solid tumor pipeline strategy
Why AstraZeneca’s ASCO 2026 rare disease and solid tumor pipeline strategy is drawing major clinical and regulatory attention. Read more.
AVCT entry at 86p is a bet on AVA6103: What Avacta Group investors should know
Avacta Group sets up a binary AVA6103 readout for late H2 2026. Here is what AVCT retail investors need to weigh before the data lands and runway runs.
AstraZeneca, Daiichi Sankyo secure FDA approval for Enhertu in two early breast cancer indications
Enhertu is moving from late-stage control to early-stage cure. AstraZeneca and Daiichi Sankyo now face the bigger test: adoption.
Racura Oncology (ASX: RAC) stock up 12.21% as MYC silencing data builds case for bisantrene relaunch
MYC is the undruggable cancer gene. Racura Oncology (ASX: RAC) says bisantrene silences it via G4 stabilisation. Three clinical trials, A$19m cash, and a 2027 inflection ahead.
4DMedical (ASX: 4DX) stock up 7.3% as Mayo Clinic adoption and GSK contract reset lung imaging story
Nuclear medicine VQ scans are a US$1 billion market. 4DMedical (ASX: 4DX) just landed Mayo Clinic, GSK, and Medicare. The question is now scan volume scaling speed.
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.